/PRNewswire/ Glenmark Pharmaceuticals, an innovation–driven, global pharmaceutical company, today announced that its subsidiary Glenmark Pharmaceuticals.
- As per this agreement, AstraZeneca remains the holder of the registration for Pulmicort Respules and will manufacture the drug. Glenmark will commercialize the product in Colombia. -
/PRNewswire/ Glenmark Pharmaceuticals, an innovation–driven, global pharmaceutical company, today announced that its subsidiary Glenmark Pharmaceuticals.
/PRNewswire/ Glenmark Pharmaceuticals, an innovation–driven, global pharmaceutical company, today announced that its subsidiary Glenmark Pharmaceuticals.